Articolul precedent |
Articolul urmator |
339 2 |
Ultima descărcare din IBN: 2023-02-23 14:03 |
SM ISO690:2012 ISTRATI, Valeriu, CALIN, Ghenadie, SCURTU, Alina, MUNTEANU, Doina, BODRUG, Nicolae, BOTEZATU, Adriana. Influența bismutului coloidal asupra metaboliților stabili ai oxidului nitric la pacienții cu boala de reflux gastroesofagian. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 230. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | ||||||
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | ||||||
|
||||||
Pag. 230-230 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Bismuth colloidal citrate preparations have a cytoprotective action on the esophageal mucosa. Cytoprotection influences all three protective levels of the mucosa: preepithelial, epithelial and postepithelial. Objective of the study. To determine the effect of bismuth tripotassium dicitrate (DeNol) on the dynamics of nitric oxide metabolites in blood serum and gastric juice in patients with erosive GERD. Material and Methods. The study included 46 patients with erosive form of GERD (age 20-60 years) and 23 practically healthy people (control group). FEGDS was performed and the concentration of NO metabolites in the blood serum was determined and gastric juice before and after treatment Treatment: gr.1 (28 patients) - basic therapy; gr.2 (18 patients) - basic therapy + De-Nol. Results. The content of stable metabolites of NO in blood serum in patients with erosive GERD was 97,35 ± 1,75 μmol/l before treatment and 85,31 ± 3,99 μmol/l after treatment in the control group. was 76.0 ± 1.61 μmol/l. The level of concentration of NO metabolites in gastric juice in the base group was 52.27 ± 3.66 mmol/l before treatment, after treatment: the level of NO metabolites decreased significantly to 34.27 ± 1.29 mmol/l l in patients treated with De-Nol compared to group 1 (46.15 ± 1.31 μmol/l). In the control group the NO metabolites in gastric juice formed 27.9 ± 1.5 μmol/l. Conclusion. 1. The concentration of NO metabolites in the blood serum and gastric juice of GERD patients in the esophagitis stage is significantly higher compared to the control group. 2. The use of De-Nol in the complex treatment of erosive GERD significantly reduces the level of NO metabolites in gastric |
||||||
Cuvinte-cheie gastroesophageal reflux disease (GERD), bismuth tripotassium dicitrate, boala de reflux gastroesofagian (BRGE), dicitrat de tripotasiu de bismut |
||||||
|